These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34010995)

  • 1. [Effects of bevacizumab on familial epistaxis caused by hereditary hemorrhagic telangiectasia].
    Zhang J; Wang XS; Wang HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2021 May; 56(5):436-441. PubMed ID: 34010995
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial.
    Peterson AM; Lee JJ; Kallogjeri D; Schneider JS; Chakinala MM; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1006-1014. PubMed ID: 32940653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of the severity and progression of epistaxis in hereditary hemorrhagic telangiectasia 1 versus hereditary hemorrhagic telangiectasia 2.
    Hunter BN; Timmins BH; McDonald J; Whitehead KJ; Ward PD; Wilson KF
    Laryngoscope; 2016 Apr; 126(4):786-90. PubMed ID: 26372311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epistaxis in children and adolescents with hereditary hemorrhagic telangiectasia.
    Gonzalez CD; Mcdonald J; Stevenson DA; Whitehead KJ; Petersen MG; Presson AP; Ding Q; Wilson KF
    Laryngoscope; 2018 Jul; 128(7):1714-1719. PubMed ID: 29171658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
    Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
    JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding.
    Beckman JD; Li Q; Hester ST; Leitner O; Smith KL; Kasthuri RS
    Orphanet J Rare Dis; 2020 Jul; 15(1):185. PubMed ID: 32660636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia.
    Khoueir N; Borsik M; Camous D; Herman P; Verillaud B
    Laryngoscope; 2019 Oct; 129(10):2210-2215. PubMed ID: 31566760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
    Parambil JG; Woodard TD; Koc ON
    Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
    Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
    Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term experience with intranasal bevacizumab therapy.
    Steineger J; Osnes T; Heimdal K; Dheyauldeen S
    Laryngoscope; 2018 Oct; 128(10):2237-2244. PubMed ID: 29469958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, controlled, double-blinded clinical trial of effect of bevacizumab injection in management of epistaxis in hereditary hemorrhagic telangiectasia patients undergoing surgical cauterization.
    Khanwalkar AR; Rathor A; Read AK; Paknezhad H; Ma Y; Hwang PH
    Int Forum Allergy Rhinol; 2022 Aug; 12(8):1034-1042. PubMed ID: 34989143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding.
    Iyer VN; Apala DR; Pannu BS; Kotecha A; Brinjikji W; Leise MD; Kamath PS; Misra S; Begna KH; Cartin-Ceba R; DuBrock HM; Krowka MJ; O'Brien EK; Pruthi RK; Schroeder DR; Swanson KL
    Mayo Clin Proc; 2018 Feb; 93(2):155-166. PubMed ID: 29395350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia].
    Xu C; Wang HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jun; 51(6):476-9. PubMed ID: 27345893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review.
    Kini SD; Yiu DW; Weisberg RA; Davila JF; Chelius DC
    Ann Otol Rhinol Laryngol; 2019 May; 128(5):467-471. PubMed ID: 30693788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.
    Al-Samkari H; Kasthuri RS; Parambil JG; Albitar HA; Almodallal YA; Vázquez C; Serra MM; Dupuis-Girod S; Wilsen CB; McWilliams JP; Fountain EH; Gossage JR; Weiss CR; Latif MA; Issachar A; Mei-Zahav M; Meek ME; Conrad M; Rodriguez-Lopez J; Kuter DJ; Iyer VN
    Haematologica; 2021 Aug; 106(8):2161-2169. PubMed ID: 32675221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: a double-blind, randomized, placebo-controlled trial.
    Riss D; Burian M; Wolf A; Kranebitter V; Kaider A; Arnoldner C
    Head Neck; 2015 Jun; 37(6):783-7. PubMed ID: 24595923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia.
    Feller CN; Adams JA; Friedland DR; Poetker DM
    Am J Otolaryngol; 2022; 43(3):103409. PubMed ID: 35216850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia.
    Simonds J; Miller F; Mandel J; Davidson TM
    Laryngoscope; 2009 May; 119(5):988-92. PubMed ID: 19194865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network.
    Lesca G; Olivieri C; Burnichon N; Pagella F; Carette MF; Gilbert-Dussardier B; Goizet C; Roume J; Rabilloud M; Saurin JC; Cottin V; Honnorat J; Coulet F; Giraud S; Calender A; Danesino C; Buscarini E; Plauchu H;
    Genet Med; 2007 Jan; 9(1):14-22. PubMed ID: 17224686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
    Dupuis-Girod S; Ginon I; Saurin JC; Marion D; Guillot E; Decullier E; Roux A; Carette MF; Gilbert-Dussardier B; Hatron PY; Lacombe P; Lorcerie B; Rivière S; Corre R; Giraud S; Bailly S; Paintaud G; Ternant D; Valette PJ; Plauchu H; Faure F
    JAMA; 2012 Mar; 307(9):948-55. PubMed ID: 22396517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.